Kenvue Absorbed by Kimberly-Clark in $40B+ Deal; KVUE Delisted from NYSE

The Quick Take

• Kenvue (KVUE) completed its $40B+ merger with Kimberly-Clark, becoming a wholly owned subsidiary.
• KVUE shareholders receive $3.50 cash plus 0.14625 shares of Kimberly-Clark per Kenvue share held.
• KVUE stock will be delisted from NYSE following completion of the deal.
• The merger reunites Kenvue's consumer health brands (formerly Johnson & Johnson) with KMB's household portfolio.

The completion of Kenvue's merger with Kimberly-Clark marks the culmination of a $40B+ transaction that transforms the consumer health sector's landscape. Kenvue, which was spun off from Johnson & Johnson in 2023, is now reintegrated into a consumer staples conglomerate as a wholly owned subsidiary. The deal exchange ratio — $3.50 in cash plus 0.14625 KMB shares per KVUE share — crystallizes value for Kenvue shareholders and sets a new benchmark for consumer health M&A multiples.

The merger creates a formidable consumer health and household products company combining Kenvue's brands (Tylenol, Neutrogena, Listerine) with Kimberly-Clark's household staples (Huggies, Kleenex, Scott). The combined entity gains scale advantages in distribution, procurement, and marketing. Kenvue's delisting from NYSE reduces standalone consumer health optionality for investors, potentially channeling interest toward remaining pure-plays like Haleon, Prestige Consumer Healthcare, or Church & Dwight.

Investors should monitor Kimberly-Clark's integration execution: synergy realization targets, margin trajectory as two cost structures merge, and whether KMB shares re-rate on deal completion. The macro variable is consumer spending resilience — both Kenvue and Kimberly-Clark are defensive staples, so their combined performance is highly sensitive to private-label competition intensity and commodity input cost trends heading into 2027.

Synthesized from 1 source.